These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8299398)

  • 21. [Does nothing else work after cisplatin in ovarian carcinoma?].
    Krafft W
    Zentralbl Gynakol; 1990; 112(21):1321-3. PubMed ID: 2278214
    [No Abstract]   [Full Text] [Related]  

  • 22. Chemotherapy in advanced ovarian cancer.
    Cruickshank DJ
    BMJ; 1991 Nov; 303(6812):1269. PubMed ID: 1747658
    [No Abstract]   [Full Text] [Related]  

  • 23. [Prognostic factors and better survival rate after the treatment of advanced ovarian cancer with neoadjuvant chemotherapy].
    Ivanov S; Ivanov S; Khadzhiolov N
    Akush Ginekol (Sofiia); 2004; 43(6):17-9. PubMed ID: 15669647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Epithelial cancer of the ovary in adults: prognostic and therapeutic study of 95 cases].
    Fignon A; Chauvet B; Body G; Calais G; Fetissof F; Kone M; Le Floch O; Lansac J
    Ann Chir; 1990; 44(4):283-9. PubMed ID: 2192681
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chemotherapy of advanced ovarian cancer].
    Hirabayashi K
    Gan No Rinsho; 1990 Aug; 36(10):1179-85. PubMed ID: 2214158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The individualization of the drug therapy of ovarian cancer].
    Novikov EG; Sergeeva NS; Obrubova GA
    Vopr Onkol; 1995; 41(2):124-5. PubMed ID: 7483407
    [No Abstract]   [Full Text] [Related]  

  • 27. Dose-dense paclitaxel for advanced ovarian cancer.
    Zeng YC; Wu R; Xu ZG; Chi F
    Lancet; 2010 Jan; 375(9711):280-1; author reply 281. PubMed ID: 20109950
    [No Abstract]   [Full Text] [Related]  

  • 28. [Chemotherapy and prognostic significance of the size of the remaining tumor in ovarian cancer].
    Petru E; Lahousen M; Pickel H; Stettner H
    Gynakol Rundsch; 1989; 29 Suppl 2():413-4. PubMed ID: 2613067
    [No Abstract]   [Full Text] [Related]  

  • 29. [Advanced cancer of the ovary. The paclitaxel-cisplatin combination as the first-line standard of treatment].
    Pecorelli S
    Recenti Prog Med; 1999 Jun; 90(6):338-41. PubMed ID: 10399475
    [No Abstract]   [Full Text] [Related]  

  • 30. [Treatment of epithelial ovarian carcinoma with cisplatin and adriamycin: analysis of factors influencing prognosis in advanced cases].
    Kamura T; Tsukamoto N; Jo S; Imachi M; Kaku T; Matsukuma K; Matsuyama T
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):2954-9. PubMed ID: 3021066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The potentials of combined chemotherapy in disseminated ovarian cancer].
    Gorbunova VA; Perevodchikova NI; Kozachenko VP; Ryzhakov VM; Marenich AF; Zhordania KI
    Akush Ginekol (Mosk); 1991 Feb; (2):54-7. PubMed ID: 1907433
    [No Abstract]   [Full Text] [Related]  

  • 32. [Combination chemotherapy of ovarian cancer with cisplatinum, aclarubicin and tegafur].
    Wada Y; Suzuki M; Shinagawa S; Saito Y; Nishiya I; Maki M; Yajima A; Hiroi M; Sato A
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2589-94. PubMed ID: 2505683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study by the Working Group in Gynecologic Oncology for therapeutic optimization in advanced FIGO IIb-IV ovarian carcinoma: cisplatin-paclitaxel vs. carboplatin-paclitaxel. AGO Protocol Ovar-3].
    Mettler L
    Zentralbl Gynakol; 1996; 118(6):379-4. PubMed ID: 8768017
    [No Abstract]   [Full Text] [Related]  

  • 34. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.
    Landen CN; Lin YG; Immaneni A; Deavers MT; Merritt WM; Spannuth WA; Bodurka DC; Gershenson DM; Brinkley WR; Sood AK
    Clin Cancer Res; 2007 Jul; 13(14):4098-104. PubMed ID: 17634535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.
    Baekelandt MM; Holm R; Nesland JM; Tropé CG; Kristensen GB
    Anticancer Res; 2000; 20(2B):1061-7. PubMed ID: 10810398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New therapy for ovarian cancer.
    Neijt JP
    N Engl J Med; 1996 Jan; 334(1):50-1. PubMed ID: 7494573
    [No Abstract]   [Full Text] [Related]  

  • 37. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of the efficacy of cisplatin-based chemotherapy in epithelial ovarian cancer; comparison with treatments employed before the cisplatin era].
    Kamura T; Tsukamoto N; Suenaga T; Kaku T; Matsukuma K; Matsuyama T
    Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1260-3. PubMed ID: 3579324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Studies of prognostic factor and chemotherapeutic effect of epithelial ovarian cancer using Cox's proportional hazard model].
    Umesaki N; Sugawa T; Yajima A; Satoh S; Terashima Y; Ochiai K; Tomoda Y; Kanoh T; Noda K; Yakushiji M
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2351-6. PubMed ID: 8259850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.